Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic disorders in which the bone marrow fails to produce sufficient healthy blood cells, leading to progressive cytopenias and, in some cases, transformation to acute leukemia. Understanding the nature of this disease is essential for patients, caregivers, and healthcare providers who encounter it in clinical and supportive settings.
Key Takeaways
- MDS is a group of bone marrow disorders characterized by defective blood cell production and abnormal cell morphology.
- Common symptoms include fatigue, frequent infections, and unexplained bleeding due to low blood cell counts.
- Risk factors include age over 60, prior chemotherapy or radiation exposure, and certain environmental toxin exposures.
- Diagnosis relies on blood tests, bone marrow biopsy, and cytogenetic analysis to classify disease severity.
- Treatment ranges from supportive care and growth factors to chemotherapy and stem cell transplantation, depending on risk category.
How Myelodysplastic Syndromes (MDS) Affect Bone Marrow Function
In healthy individuals, bone marrow acts as the body’s blood cell factory, producing red blood cells, white blood cells, and platelets through a tightly regulated process called hematopoiesis. In patients with MDS, this process is disrupted at the stem cell level, where genetic mutations cause immature blood cells—known as blasts—to develop abnormally and fail to mature into fully functional cells. These dysfunctional cells accumulate in the marrow and periphery, crowding out healthy precursors and impairing the marrow’s productive capacity.
The term myelodysplastic syndromes bone marrow failure captures the core pathology: the marrow is hypercellular in many cases yet paradoxically underperforms, producing cells that die prematurely through a process called intramedullary apoptosis. This ineffective hematopoiesis results in anemia, neutropenia, and thrombocytopenia—the three hallmark cytopenias of MDS. Each cytopenia carries its own clinical consequences, ranging from chronic fatigue and breathlessness to heightened susceptibility to infection and bleeding episodes.
MDS is classified into subtypes based on the proportion of blasts in the marrow, specific chromosomal abnormalities, and the number of affected cell lineages. The World Health Organization (WHO) classification system, last revised in 2022, distinguishes multiple subtypes including MDS with low blasts, MDS with excess blasts, and MDS with isolated del(5q). Each subtype carries a different prognosis and guides therapeutic decision-making. Approximately 10–15% of MDS cases progress to acute myeloid leukemia (AML), making accurate subtype classification clinically critical.
MDS Symptoms, Causes, and Risk Factors
The clinical presentation of MDS varies considerably depending on which blood cell lineages are most affected. Patients often experience symptoms slowly and may initially attribute them to normal aging, which can delay diagnosis. Anemia—resulting from insufficient red blood cell production—is the most common presenting feature, causing fatigue, pallor, shortness of breath, and reduced exercise tolerance. When platelet counts fall, patients may notice easy bruising, prolonged bleeding from minor cuts, or petechiae. Low white blood cell counts, particularly neutropenia, increase vulnerability to bacterial and fungal infections that may be severe or recurrent.
The underlying MDS symptoms and causes in bone marrow are rooted in acquired somatic mutations affecting hematopoietic stem cells. Mutations in genes such as SF3B1, TET2, ASXL1, RUNX1, and TP53 have been frequently identified in MDS patients and contribute to the dysregulated differentiation and survival of marrow progenitor cells. These mutations are not inherited in most cases; rather, they accumulate over a lifetime through environmental exposures or replication errors. In a subset of patients, MDS arises as a secondary condition following prior cytotoxic therapy for another cancer—this is referred to as therapy-related MDS and generally carries a worse prognosis.
Common Risk Factors for MDS
Several well-established risk factors increase an individual’s likelihood of developing this disorder. Age is among the most significant—MDS is predominantly a disease of older adults, with a median age at diagnosis of approximately 70 years, and the American Cancer Society estimates around 13,000 new cases are diagnosed annually in the United States alone. Additional risk factors include:
- Prior treatment with alkylating chemotherapy agents or radiation therapy
- Occupational or environmental exposure to benzene, heavy metals, or pesticides
- Cigarette smoking, which has been associated with increased MDS risk in epidemiological studies
- Certain inherited bone marrow failure syndromes, such as Fanconi anemia or dyskeratosis congenita
- Male sex, as MDS occurs slightly more frequently in men than in women
While these risk factors are established, many individuals with MDS have no identifiable predisposing condition, highlighting the role of stochastic mutational events during normal aging as a primary driver of disease onset.
Diagnosing and Treating MDS Bone Marrow Failure
Establishing a diagnosis requires a systematic and thorough evaluation, as MDS can mimic other conditions including nutritional deficiencies, aplastic anemia, and other myeloid neoplasms. The diagnostic workup typically begins with a complete blood count (CBC) and peripheral blood smear, which may reveal characteristic features such as macro-ovalocytes, hypersegmented neutrophils, or circularly shaped platelets. These findings prompt further investigation through bone marrow aspiration and biopsy, the gold-standard procedures for confirming MDS. Pathologic review assesses cellularity, blast percentage, and morphological dysplasia across one or more cell lineages.
Cytogenetic analysis—including conventional karyotyping and fluorescence in situ hybridization (FISH)—is essential because chromosomal abnormalities such as deletion 5q, monosomy 7, and trisomy 8 carry prognostic significance and influence treatment planning. Next-generation sequencing panels are increasingly incorporated into the diagnostic process to identify somatic mutations that refine risk stratification. The International Prognostic Scoring System–Revised (IPSS-R) integrates blast percentage, cytogenetics, and individual cytopenia depths to classify patients into very-low, low, intermediate, high, and very-high risk groups, each associated with different expected outcomes.
The myelodysplastic syndromes diagnosis and treatment options span a wide spectrum depending on risk category, patient age, and overall fitness. For lower-risk patients, goals center on managing cytopenias and preserving quality of life. Erythropoiesis-stimulating agents (ESAs) such as epoetin alfa or darbepoetin alfa are commonly used for transfusion-dependent anemia. Lenalidomide is the preferred agent for patients with MDS associated with isolated del(5q), as it produces red blood cell transfusion independence in a substantial proportion of treated individuals. Luspatercept, approved by the FDA in 2020, represents a newer option for anemia in lower-risk MDS with ring sideroblasts.
Treatment Approaches for Higher-Risk MDS
For patients classified as intermediate-2 or high risk by the IPSS-R, the treatment landscape shifts toward disease-modifying therapy. Hypomethylating agents (HMAs) such as azacitidine and decitabine remain the standard of care for higher-risk MDS patients who are not candidates for intensive therapy. These agents work by reversing aberrant DNA methylation patterns that suppress tumor suppressor gene expression, thereby partially restoring normal hematopoiesis. Response rates vary, but HMAs can prolong overall survival and delay progression to AML in eligible patients.
Allogeneic hematopoietic stem cell transplantation (HSCT) remains the only potentially curative intervention for MDS. It is typically reserved for younger patients or those with adequate performance status who have a suitable donor. Outcomes are influenced by disease risk at transplant, donor compatibility, and conditioning regimen intensity. Research into novel agents—including venetoclax combinations, IDH inhibitors, and immune checkpoint inhibitors—is ongoing and may expand options in the coming years.
Outlook and Disease Progression in Myelodysplastic Syndromes
The prognosis in MDS is highly variable and depends on disease subtype, cytogenetic profile, mutation burden, and individual patient characteristics. Median survival ranges from less than one year in very-high-risk patients to more than eight years in very-low-risk categories, based on IPSS-R stratification data. The primary causes of morbidity and mortality in MDS include complications from severe cytopenias—particularly infections due to neutropenia and hemorrhage from thrombocytopenia—as well as transformation to AML.
Understanding bone marrow failure in MDS patients also requires acknowledging the psychological and functional burden the disease places on those affected. Chronic transfusion dependence, frequent medical visits, and uncertainty about disease course can substantially diminish quality of life. Multidisciplinary supportive care—including management of transfusion-related iron overload with chelation therapy, infection prophylaxis, and psychosocial support—is an integral component of comprehensive MDS management.
Disease monitoring involves regular blood counts and periodic bone marrow reassessment to detect clonal evolution or blast progression. Patients and clinicians should maintain ongoing, open communication about evolving treatment goals, especially as the disease progresses or new therapeutic options become available. Advances in genomic profiling continue to improve the ability to predict outcomes and personalize treatment strategies, offering cautious optimism for patients navigating this complex disorder.
Frequently Asked Questions
Is MDS considered a form of cancer?
MDS is classified as a clonal hematopoietic neoplasm and is generally considered a type of blood cancer. Although it differs from solid tumors, its origin in abnormal stem cell clones, potential for progression to acute myeloid leukemia, and responsiveness to cancer-directed therapies place it firmly within the oncology spectrum. Most major cancer registries, including the National Cancer Institute, categorize MDS as a hematologic malignancy.
Can MDS be cured without a stem cell transplant?
For most patients, allogeneic stem cell transplantation remains the only established curative option. However, not all patients are eligible due to age, comorbidities, or lack of a compatible donor. Non-transplant therapies can control symptoms and slow disease progression for years but are generally not curative. Ongoing clinical trials are evaluating novel combinations that may eventually offer curative potential without the risks associated with transplantation.
At what point does MDS become acute myeloid leukemia?
MDS is considered to have transformed to acute myeloid leukemia (AML) when the proportion of blast cells in the bone marrow reaches or exceeds 20%, as defined by the WHO classification. This threshold is used because blast levels above 20% are associated with a distinctly more aggressive clinical course. Not all MDS patients progress to AML; risk of transformation is highest in individuals with higher-risk cytogenetics, complex karyotypes, or TP53 mutations.
| Risk Category | Blast % in Marrow | Approximate Median Survival | AML Transformation Risk |
|---|---|---|---|
| Very Low | <2% | >8 years | Very low |
| Low | <5% | ~5 years | Low |
| Intermediate | <5–10% | ~3 years | Moderate |
| High | 10–20% | ~1.5 years | High |
| Very High | 10–20% with adverse features | <1 year | Very high |
